BioSpace News Archive

CytomX Therapeutics, Inc. and Astellas Pharma Inc. announced they have entered into a strategic collaboration agreement focused on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.

Following Federal Policy Changes, Healthcare Specialist Vanguard Communications Presents “Patient in a Pocket” Webinar About Conducting Patient Appointments Virtually Via Common Apps

- In the months since the global public health crisis rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. The crisis has catalyzed the development of novel vaccines across

IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer, effective April 1, 2020.

ResMed (NYSE: RMD) (ASX: RMD) has released the following statement from CEO Mick Farrell regarding the evolving coronavirus disease (COVID-19) outbreak:

Health Canada recently completed testing on a number of USB chargers that plug into an electrical outlet intended for use with cell phones, tablets and other devices as part of a planned national compliance and enforcement project.

Eyenovia, Inc. announced that it has received subscriptions for a private placement in the amount of approximately $6.0 million of units at a price to the public of $2.21425 per unit.

AIkido Pharma Inc. announced that its Board of Directors has acted to preserve and protect the Company’s valuable income tax net operating loss carryforwards by adopting a stockholder rights plan in the form of a Section 382 Rights Agreement, dated as of March 23, 2020, by and between the Company and VStock Transfer LLC.

Company Benefits from Unique Chinese, Hong Kong, Macau Diagnostic Patent Rights, and Closes Deal to Help America Now